HGF Human shRNA Lentiviral Particle (Locus ID 3082)

CAT#: TL312467V

HGF - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Specifications

Product Data

• Locus ID: 3082
• Synonyms: DFNB39; F-TCF; HGFB; HPTA; SF
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_000601, NM_001010931, NM_001010932, NM_001010933, NM_001010934, NM_001010931.1, NM_001010931.2, NM_001010933.1, NM_001010933.2, NM_000601.2, NM_000601.3, NM_000601.4, NM_000601.5, NM_001010934.1, NM_001010934.2, NM_001010932.1, NM_001010932.2, BC022308, BC063485, BC105797, BC130284, BC130286, BM153501, BM971901, NM_001010931.3, NM_000601.6, NM_001010933.3, NM_001010934.3, NM_001010932.3
• UniProt ID: P14210
• Summary: This gene encodes a protein that binds to the hepatocyte growth factor receptor to regulate cell growth, cell motility and morphogenesis in numerous cell and tissue types. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate alpha and beta chains, which form the mature heterodimer. This protein is secreted by mesenchymal cells and acts as a multi-functional cytokine on cells of mainly epithelial origin. This protein also plays a role in angiogenesis, tumorogenesis, and tissue regeneration. Although the encoded protein is a member of the peptidase S1 family of serine proteases, it lacks peptidase activity. Mutations in this gene are associated with nonsyndromic hearing loss. [provided by RefSeq, Nov 2015]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).